HOME >> MEDICINE >> NEWS
St. Jude leukemia therapy overcomes differences in treatment outcome between black, white children

(MEMPHIS, TENN.--October 14, 2003) Investigators at St. Jude Children's Research Hospital have found that black children are equally likely as white children to benefit from improved treatment for acute lymphoblastic leukemia (ALL), if given equal access to the most advanced therapies.

This finding--that black and white children had virtually equal rates of survival over 10 years--contrasts with the results of clinical studies from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). The POG and CCG multi-center studies showed that black children lagged behind white children in the cure rate for ALL.

Even though black children referred to St. Jude were more likely to have high-risk leukemia and be socioeconomically underprivileged, they enjoyed the same excellent treatment results as white children, according to Ching-Hon Pui, M.D., director of the St. Jude Leukemia/Lymphoma division.

Pui is senior author of this study, which appears in the Oct. 15 issue of the Journal of the American Medical Association. Despite black children presenting with more bulky disease at diagnosis and having unfavorable genetic subtypes of leukemia, the St. Jude treatment was able to achieve high cure rates that were equal in black and white children.

"It's remarkable that, although African-American children with ALL are more likely than white children to have high-risk leukemia, the black children in our studies derived as much benefit from therapy as white children," said William Evans, Pharm.D., St. Jude scientific director and a co-author of the study. "This is apparently due to the modifications we made to our previous, very successful therapies for ALL, making those treatments even more effective."

One factor contributing to the treatment success rate among black children is that all St. Jude patients received a personally tailored approached to treatment--called risk-directed therapy--regardless of health insurance s
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
14-Oct-2003


Page: 1 2

Related medicine news :

1. Both inherited traits and tumor mutations affect response to treatment of leukemia
2. Plant derivative attacks the roots of leukemia
3. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
4. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
5. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
6. New leukemia drug shows promise in overriding all Gleevec resistance
7. Cord blood transplantation now a viable option for adult leukemia patients
8. Peptide vaccine can produce complete remission in myeloid leukemia patients
9. Methylphenidate improves attention, behavior of children surviving leukemia, brain tumors
10. Obesity linked to another cancer - leukemia in older women
11. Improved acute lymphoblastic leukemia treatment offers hope for eliminating irradiation

Post Your Comments:
(Date:8/20/2014)... Taking the widely used antibiotic clarithromycin may boost ... new study suggests. Because millions of people receive ... said the Danish researchers behind the study. However, they ... guidelines for the use of the drug should not ... heart expert wasn,t surprised by the finding, however. ...
(Date:8/20/2014)... According to a new market research report ... Crystal, Microblinds, Thermographic and Photochromics), by application (Architectural, ... geography - Global Forecast to 2014 - 2020", ... market was worth $1581.4 Million in 2013, and ... at an estimated CAGR of 20% from 2014 ...
(Date:8/20/2014)... Washington, D.C. (PRWEB) August 20, 2014 ... has received a five-year, $1.24 million Science Education ... of Health to support NAHN’s collaborative project with ... Models in Health Careers. , This collaborative NIH ... need for cultural and linguistic diversity among health ...
(Date:8/20/2014)... The report “Automotive Airbag and Seat Belt Market ... Geography - Trends and Forecasts 2014 - 2019”, ... and seatbelt market in terms of volume and ... the coming years as well as covers review ... challenges, legislation trends, market dynamics, competitive landscape, and ...
(Date:8/20/2014)... Oxnard dentist and noted international ... Art Institute, is presenting at the Spectrum Day Vancouver ... on All-on-4 dental implants in a presentation ... at 12:40 p.m. Sept. 20 at the Empire Landmark ... , “The All-on-4 procedure gives patients a set of ...
Breaking Medicine News(10 mins):Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 2Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 3
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014 ... Japanese electrophysiology (EP) mapping and ablation device ... increasingly use ablation to treat atrial fibrillation ... a primary treatment option for AF will ... for this application, such as advanced loop ...
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
Cached News: